Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 408

1.

Anti-parietal cell antibody and serum pepsinogen assessment in screening for gastric carcinoma.

Sugiu K, Kamada T, Ito M, Kaya S, Tanaka A, Kusunoki H, Hata J, Haruma K.

Dig Liver Dis. 2006 May;38(5):303-7. Epub 2006 Mar 20.

PMID:
16549394
2.

Helicobacter pylori infection and gastric autoimmune diseases: is there a link?

Presotto F, Sabini B, Cecchetto A, Plebani M, De Lazzari F, Pedini B, Betterle C.

Helicobacter. 2003 Dec;8(6):578-84.

PMID:
14632671
3.

Normal serum pepsinogen I levels in adults: a population-based study with special reference to Helicobacter pylori infection and parietal cell antibodies.

Hokkanen S, Kosunen TU, Sarna S, Miettinen A, Salomaa A, Aromaa A, Knekt P, Rautelin HI.

Scand J Clin Lab Invest. 2005;65(4):291-9.

PMID:
16076684
4.

Plasma ghrelin concentration correlates with the levels of serum pepsinogen I and pepsinogen I/II ratio--a possible novel and non-invasive marker for gastric atrophy.

Suzuki H, Masaoka T, Hosoda H, Nomura S, Ohara T, Kangawa K, Ishii H, Hibi T.

Hepatogastroenterology. 2004 Sep-Oct;51(59):1249-54.

PMID:
15362725
5.

Relationship between Helicobacter pylori infection, atrophic gastritis and gastric carcinoma in a Japanese population.

Asaka M, Kato M, Kudo M, Katagiri M, Nishikawa K, Yoshida J, Takeda H, Miki K.

Eur J Gastroenterol Hepatol. 1995 Aug;7 Suppl 1:S7-10.

PMID:
8574741
6.

Serum pepsinogen I and II levels in various gastric disorders with special reference to their use as a screening test for carcinoma stomach.

Parthasarathy G, Maroju NK, Kate V, Ananthakrishnan N, Sridhar MG.

Trop Gastroenterol. 2007 Oct-Dec;28(4):166-70.

PMID:
18416347
7.

Relationship between Helicobacter pylori status and serum pepsinogens as serologic markers in atrophic gastritis.

Bölükbaş C, Bölükbaş FF, Ovünç O, Kiliç G, Dalay R, Güven H, Uras F, Yardimci TK, Sökmen MH, Agan AF, Pişkinpaşa N.

Turk J Gastroenterol. 2006 Sep;17(3):172-6.

8.

Effect of Helicobacter pylori infection combined with CagA and pepsinogen status on gastric cancer development among Japanese men and women: a nested case-control study.

Sasazuki S, Inoue M, Iwasaki M, Otani T, Yamamoto S, Ikeda S, Hanaoka T, Tsugane S; Japan Public Health Center Study Group.

Cancer Epidemiol Biomarkers Prev. 2006 Jul;15(7):1341-7.

9.

Serological comparison of serum pepsinogen and anti-parietal cell antibody levels between Japanese and German patients.

Ito M, Haruma K, Kaya S, Kamada T, Kim S, Sasaki A, Sumii M, Tanaka S, Yoshihara M, Wagner S, Chayama K.

Eur J Gastroenterol Hepatol. 2002 Feb;14(2):123-7.

PMID:
11981335
10.

Cancer development based on chronic active gastritis and resulting gastric atrophy as assessed by serum levels of pepsinogen and Helicobacter pylori antibody titer.

Yoshida T, Kato J, Inoue I, Yoshimura N, Deguchi H, Mukoubayashi C, Oka M, Watanabe M, Enomoto S, Niwa T, Maekita T, Iguchi M, Tamai H, Utsunomiya H, Yamamichi N, Fujishiro M, Iwane M, Takeshita T, Ushijima T, Ichinose M.

Int J Cancer. 2014 Mar 15;134(6):1445-57. doi: 10.1002/ijc.28470. Epub 2013 Oct 3.

11.

Helicobacter pylori eradication improves gastric histology and decreases serum gastrin, pepsinogen I and pepsinogen II levels in patients with duodenal ulcer.

Pimanov SI, Makarenko EV, Voropaeva AV, Matveenko ME, Voropaev EV.

J Gastroenterol Hepatol. 2008 Nov;23(11):1666-71. Epub 2007 Jun 7.

PMID:
17559360
12.

Gastric parietal cell antibodies, Helicobacter pylori infection, and chronic atrophic gastritis: evidence from a large population-based study in Germany.

Zhang Y, Weck MN, Schöttker B, Rothenbacher D, Brenner H.

Cancer Epidemiol Biomarkers Prev. 2013 May;22(5):821-6. doi: 10.1158/1055-9965.EPI-12-1343. Epub 2013 Mar 1.

13.

Role of Helicobacter pylori infection and chronic inflammation in gastric cancer in the cardia.

Egi Y, Ito M, Tanaka S, Imagawa S, Takata S, Yoshihara M, Haruma K, Chayama K.

Jpn J Clin Oncol. 2007 May;37(5):365-9. Epub 2007 Jun 19.

PMID:
17578895
14.

Prevalence of Helicobacter pylori infection and atrophic gastritis in Latvia.

Leja M, Cine E, Rudzite D, Vilkoite I, Huttunen T, Daugule I, Rumba-Rozenfelde I, Pimanov S, Liepniece-Karele I, Pahomova J, Purmalis K, Eglitis J, Pirags V, Dzerve V, Erglis A.

Eur J Gastroenterol Hepatol. 2012 Dec;24(12):1410-7. doi: 10.1097/MEG.0b013e3283583ca5.

PMID:
23114744
15.
16.

Severity of atrophic gastritis related to antiparietal cell antibody and gastric carcinogenesis, including p53 mutations.

Taguchi A, Ohmiya N, Itoh A, Hirooka Y, Niwa Y, Mori N, Goto H.

J Gastroenterol Hepatol. 2006 Mar;21(3):545-51.

PMID:
16638096
17.

[Serological diagnosis of atrophic gastritis with a combination of pepsinogen I and II, gastrin-17 and anti-Helicobacter pylori antibodies].

Valle Muñoz J, Artaza Varasa T, López Pardo R, Rodríguez Merlo R, Pérez Grueso MJ, Martín Escobedo R, Alcántara Torres M, Cuena Boy R, Carrobles Jiménez JM.

Gastroenterol Hepatol. 2007 Dec;30(10):567-71. Spanish.

PMID:
18028850
18.
19.

Two-thirds of atrophic body gastritis patients have evidence of Helicobacter pylori infection.

Annibale B, Negrini R, Caruana P, Lahner E, Grossi C, Bordi C, Delle Fave G.

Helicobacter. 2001 Sep;6(3):225-33.

PMID:
11683925
20.

Serum pepsinogen levels, Helicobacter pylori CagA Status, and cytokine gene polymorphisms associated with gastric premalignant lesions in Costa Rica.

Con SA, Con-Wong R, Con-Chin GR, Con-Chin VG, Takeuchi H, Valerín AL, Echandi G, Mena F, Brenes F, Yasuda N, Araki K, Sugiura T.

Cancer Epidemiol Biomarkers Prev. 2007 Dec;16(12):2631-6.

Supplemental Content

Support Center